Phase 1 interim: nadir prekallikrein by weight-based dose
Phase 1: 6 mg/kg single dose
Phase 1: 300 mg (plus or minus 25 mg) single fixed dose, prospectus
Phase 1: 300 mg single dose, congress reports
Phase 1: 300 mg single dose, sponsor press release
Phase 1: 300 mg dose cohort as attributed in the November 2026 corporate presentation
Onset: lag to full prekallikrein inhibition
Phase 2a: prekallikrein reduction in participants with HAE compared with healthy volunteers
Phase 2a: prekallikrein suppression threshold associated with absence of attacks
Preclinical studies: serum prekallikrein after a single 4 mg/kg dose in nonhuman primates
Preclinical studies: prekallikrein suppression at 200 mg/kg in nonhuman primates
Preclinical studies: projected dosing interval from nonhuman primate data
Nonclinical toxicology: nonhuman primates and rabbits
Nonclinical toxicology: off-target effects observed in rats